SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that re-prioritizes promising science and pioneers efficient pathways for drug development for patients with severe, rare diseases and cancer.
It starts with patients. The inspiration for the science. At SpringWorks Therapeutics, we see the ground-breaking potential in that science. We see what it could mean for people without options, without treatments, and without hope.
Launched in September 2017 with promising clinical therapies from Pfizer, we have an experienced management team led by accomplished drug developers.
SpringWorks is planning to launch two potentially registrational trials during 1H19 in rare oncology indications with no approved therapies. One of these is a MEK inhibitor being developed for neurofibromatosis as well as a backbone for rational combination therapies in multiple solid tumors through partnerships
Within SpringWorks, the lead for the project will reside within Medical Affairs in collaboration with our clinical development team.
SpringWorks will bring expertise in clinical trial design and execution as well as the design on natural history studies to the project.
As a lead company in the development of a promising therapeutic for patients living with neurofibromatosis, we have the expertise to contribute to WP7.